Dolutegravir (DTG) is the primary medicine used for HIV-infected patients. It is to be used to treat both HIV-infected adults who have never taken HIV treatment and HIV-infected adults who have previously taken HIV treatment (treatment-experienced), including those who have been treated with other integrase strand transfer inhibitors. Dolutegravir, an HIV integrase-strand transfer inhibitor, blocks the function of HIV integrase that is required for viral replication. Dolutegravir is approved for kids of ages over 12-13 years and older weighing at least over 40 kilograms (kg) who are treatment-naive or treatment-experienced but have not previously taken other integrase strand transfer inhibitors. Dolutegravir, antiretroviral treatment for HIV-1 infection, was approved by the US in June 2020. It is indicated to be used in combination with other antiretroviral medications. It is indicated for children who have not been treated for HIV before. Side effects that are common include headaches, insomnia, fatigue, blood sugar highs, and trouble sleeping. Side effects that are severe may include liver problems and allergic reactions. It is possible that pregnancy could cause harm to the baby. It is not known if breastfeeding is safe. The U.S. Food and Drug Administration (FDA), announced in February 2013 that Dolutegravir would be approved quickly after that Dolutegravir was approved in the United States for medical use on August 13, 2013. The World Health Organization (WHO), recommends DTG for HIV-positive people as first and second-line treatment.

The price for Dolutegravir oral tablets 10 mg is approximately $410 per 30 tablet supply, depending on which pharmacy you visit. Dolutegravir, sold under the brand name Tivicay.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Dolutegravir offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for Dolutegravir manufacturers and Dolutegravir suppliers that you are looking for. These also enable you to check the dossier status of Dolutegravir, and the GMP approvals of the different variants of Dolutegravir. Also, each manufacturer or supplier product description contains essential information about Dolutegravir including clinical data, stability zones, countries where Dolutegravir is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over Dolutegravir offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and ordering processes. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers or suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that Dolutegravir manufacturers list has, we qualify their companies before they are boarded on the platform. This allows us to screen Dolutegravir manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.